Vet360, December 2016 - Page 22

ADVERTORIAL Exploring the Latest Evidence Based Medicine in Veterinary Cardiology Every 4 years, Boehringer Ingelheim Animal Health hosts an International Cardiology Veterinary Symposium (ICVS), and explores the forefront of modern veterinary cardiology. The ICVS, held in Dubrovnik, Croatia, 21-23 October 2016, was well attended by over 280 vets. The South African delegation included Leon Muller (Boehringer Ingelheim’s National Sales Manager), Dr. Frank Kettner (Tygerberg Animal Hospital), Dr. Tanya Schoeman (Cape Animal Medical Centre), Dr. Phil Rees (Westville Veterinary Hospital), Dr. Alain Carter (Fourways Veterinary Hospital) and Dr. Paulo Pazzi (University of Pretoria, Faculty of Veterinary Science, Small Animal Medicine). The event was organised with the assistance of a distinguished scientific programme committee that included the lead investigators of the recently published EPIC (Evaluation of Pimobendan in Cardiomegaly) Study: • Professor Adrian Boswood, Department of Veterinary Clinical Sciences, The Royal Veterinary College, London, UK • Professor Sonya Gordon, Department of Small Animal Clinical Science, Texas A&M College of Veterinary Medicine and Biomedical Sciences, USA • Professor Jens Häggström, Department of Veterinary Clinical Sciences, Swedish University of Agricultural Sciences, Uppsala, Sweden The programme explored a variety of topics: • Recent veterinary cardiology research • Developments in preclinical myxomatous mitral valve disease (MMVD) and dilated cardiomyopathy (DCM) • New findings in MMVD and DCM The South African Specialists who attended the ICVS ’16, had the following comments to make about the overall symposium content and the EPIC trial presented to them by the lead investigators: Dr. Tanya Schoeman: "The content of the symposium was exceptional. I thought the EPIC trial was a very well designed study with convincing evidence to change the way we approach preclinical cardiac cases. The EPIC trial results are a complete game changer. I will now urge all clients to start pimobendan treatment in all cases of preclinical cardiac disease in dogs. I would definitely like to see more studies in cats!” vet360 Issue 06 | DECEMBER 2016 | 22 Dr. Alain Carter “The ICVS allows exchange of ideas and discussions around current topics in veterinary cardiology.  The most common heart condition in veterinary science is mitral valve disease and this was discussed in detail with regards to past and present recommendations. A look at future interventional therapies with valve replacements was fascinating, although still many years way from clinical application.  Some early research is going on around serotonin blockers in stopping the inflammatory processes around the development of valvular degeneration in the very early stages. The use of pimobendan in cats was discussed and this holds some promise. A survey amongst the delegates looking at the clinical approach to management of heart disease was interesting and gave a worldwide perspective to our position in South Africa.” “The EPIC trial results were discussed in detail.  The results are profound with regards to how we are going to manage mitral valve disease in dogs currently and into the future.  The QUEST trial which was released in 2008 confirmed that pimobendan is essential in the management of congestive heart failure associated with mitral valve disease.  The EPIC trial which was the largest veterinary trial to date looked at the use of pimobendan in the preclinical stages of mitral valve disease and it showed that its use in Stage B2 delayed the onset of heart failure for an average of 15 months. Considering that the average life expectance of a patient with congestive heart failure secondary to mitral valve disease is 1 year delaying this development by 15 months is huge.” Dr. Frank Kettner “The symposium was a fantastic experience, well organised and delivered high quality content with the best of the best specialists in cardiology giving us great insight in the way they treat heart failure in dogs and cats. The EPIC study now finally gives us evidence based guidelines to treat dogs with mitral valve insufficiency in the preclinical setting. This will certainly help us guide our clients in making treatment decisions.”